What insurance policy changes affect HCPCS J3394?

There are 10 tracked policy changes affecting HCPCS J3394, including updates from Medi-Cal, Harvard Pilgrim Health Care, Arkansas Medicaid. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J3394?

Payers that have issued tracked updates for HCPCS J3394 include: Medi-Cal, Harvard Pilgrim Health Care, Arkansas Medicaid, Connecticut Medicaid (HUSKY Health), Humana, Molina Healthcare, Maryland Medicaid, Illinois Medicaid - HFS, UnitedHealthcare.

How do I get notified when HCPCS J3394 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J3394. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J3394?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J3394 — Injection, lovotibeglogene autotemcel, per treatment: Insurance Policy Changes

J3394 Insurance Policy Changes

HCPCS J3394 is officially defined as "Injection, lovotibeglogene autotemcel, per treatment." HCPCS J3394 is referenced in 10 tracked payer policy changes from Medi-Cal, Harvard Pilgrim Health Care, and 7 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J3394 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

2025.76 - Provider Bulletin - Cell and Gene Therapy for Sickle Cell Disease - Revised 12.18.2025

Connecticut Medicaid (HUSKY Health)·Effective Jan 1, 2026

Connecticut Medicaid (HUSKY Health) establishes new billing procedures for cell and gene therapy treatments for Sickle Cell Disease under the CMS CGT Access Model. Hospitals must bill CGT products separately on outpatient claims using specific HCPCS codes and obtain separate prior authorizations for both the CGT product and inpatient admission.

J3394 Insurance Policy Changes

Cell and Gene Therapy Access Model Update: UB-04 Claim Form is Required for Reimbursement of HCPCS Codes J3392 and J3394

Point32Health medical drug program updates

Coverage for Casgevy (J3392) and Lyfgenia (J3394) for the Sickle Cell Gene Therapy Model

2025.76 - Provider Bulletin - Cell and Gene Therapy for Sickle Cell Disease - Revised 12.18.2025

Gene Therapy Treatments for Sickle Cell Disease - Medicare Advantage (Revised)

Q1 2026 Provider Newsletter

PT 43-26: Cell and Gene Therapy Access Model for Sickle Cell Disease

Cell Gene Therapy (CGT) Access Model

Point32Health medical drug program updates

North Carolina Medicaid: Prior authorization updates for specialty pharmacy medications